Aarti Drugs Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xt5sx9fw5im7pyeobi41e04v.pdf

Key Takeaways


The Price-Versus-Volume Disconnect

Adhish Patil: "the thing is, in the month of September there was some price cuts, and because there was a price cut, that was a new price cut which was not there before. So, if that price cut did not happen then with all the high-cost inventory would have been already considered in this quarter itself, nothing would have left."

Export Demand: The Unmodeled Headwind

Adhish Patil: "the export market is a new factor which we did not account for when we gave the guidance of around 10%. So, that has impacted our guidance. The September quarter was weak. Right now still all these because of geopolitical tensions things look little dicey."

Margin Walk: A Recovery Interrupted

Adhish Patil: "One is the crude levels should not go up sharply from here, the current year is still okay, there should not be much volatility in the market. And these geopolitical tensions what are happening right now globally that should ease out, because that will definitely impact business quite a lot in terms of ease of transaction."

Capacity & Projects: Building for a Recovery


USFDA Audit: Waiting for the Knock

Adhish Patil: "they said that the response is complete. So, they don't need any more information as far as the response is concerned. However, by that time they had not intimated their Indian counterparts to initiate the audit. But they told us that told us to follow up by the end of October or start of November to check with them again."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue growthAchieve 5% to 10% growth (revised down from ~10%)FY24
EBITDA margin improvementImprove by 1%, reaching ~13%H2 FY24
Gross contribution improvementIncrease by at least 0.5% to 1%H2 FY24
Tarapur dermatology projectCommercial production startedOctober 2023 (achieved)
Salicylic acid side projectStart commercial batchesBy December end
SAYKHA Greenfield projectStart work, then commercial batches 15-30 days laterEnd of January / February-March
Total FY24 CAPEXRs. 250 to Rs. 300 croresFY24
All CAPEX plans (Gujarat, Sayakha, Tarapur)CompletedH2 FY24
FY25 CAPEXNot beyond Rs. 150 croresFY25
Methylamine capacity utilization~35% (subject to process settling)FY25
New capacity utilization (analyst math)One-third of ~Rs. 1,000 crores potentialFY25
USFDA audit follow-upFollow up with FDA on audit initiationEnd of October / start of November

Key Metrics

MetricQ2 FY24
Consolidated revenue₹642 cr, decline of 6.6% YoY
H1FY24 consolidated revenue₹1,304 cr, flat YoY (vs ₹1,310 cr)
EBITDA₹77 cr, vs ₹74 cr YoY
EBITDA margin12.0%
PAT₹40 cr
PAT margin6.2%
H1FY24 EBITDA margin12.4%
H1FY24 PAT₹88 cr
H1FY24 PAT margin6.7%
API segment volume growth~10% YoY
API segment revenue decline6.2% YoY, due to downward rate variance
Formulation segment revenue₹86.6 cr, growth of 5.0% YoY, exports contribution ~49%
Standalone revenue₹578 cr, decline of 7.6% YoY
Standalone domestic revenue growth~1% YoY on value basis
Standalone exports de-growth~20% YoY
Net debt₹589 cr as on 30 Sep 2023, vs ₹609 cr as on 31 Mar 2023
Net debt-to-equity0.49x
Net debt to total assets0.25x
API negative price variation QoQ(-7.5%), Sep 23 vs Jun 23 quarter
API negative price variation YoY(-16%), Sep 23 vs Sep 22
API QoQ volume growth~5%
Capacity utilization (existing facilities)74%–75%, slightly up vs Jun 23 quarter
H1FY24 CAPEX incurred₹109 cr
FY24 CAPEX guidance₹250–300 cr
FY25 CAPEX guidanceNot beyond ₹150 cr
Revenue growth guidance FY245% to 10% for the full year
Gross margin improvement expected in H2FY240.5% to 1% improvement in net contribution
EBITDA margin guidance H2FY24~13%
Inventory days94–95 days
New capacity additional revenue potential₹500–600 cr from FY24 CAPEX
New capacity utilization expected in FY25~33% (one-third)